Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient [2]

Liver International

Volumn 28, Issue 5, 2008, Pages 718-720

  Martinez Montiel, Pilar ^a   Antonio Solis, Jose ^a   Antonio Chirinos, Juan ^a   A Casis, Begoń ^a   Sánchez, Fernando ^a   Rodríguez, Sarbelio ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; OMEPRAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ABDOMINAL DISCOMFORT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CAUCASIAN; DRUG WITHDRAWAL; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; LIVER FUNCTION TEST; MALAISE; MALE; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REACTIVATION;

AGED; AMYLOIDOSIS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE;

EID: 42149109018     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01665.x     Document Type: Letter

References (7)

1. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 54: 1363-5.
2. Persico E, De Renzo A, La Mura V, et al. Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: The need for early diagnosis in anti-Hbc positive patients. Gut 2007; 56: 1470-1.
3. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflammatory Bowel Disease 2007; 13: 509.
4. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-8.
5. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
6. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
7. Marinos G, Naoumov NV, Rossol S, et al. Tumor necrosis factor in patients with chronic hepatitis B infection. Gastroenterology 1995; 108: 1453-63.